Comparative activities of UK-49,858 and amphotericin B against Blastomyces dermatitidis infections in mice.
UK-49,858, a new antifungal triazole derivative, was compared with amphotericin B in the treatment of pulmonary infections by Blastomyces dermatitidis in male BALB/cByJ mice. Administration of UK-49,858 in daily doses of 25 or 50 mg/kg for 21 days gave 30 and 100% survival rates, respectively. These results compared with 100% mortality in infected controls and 100% survival among mice treated with amphotericin B. UK-49,858 did not eradicate the fungus from the lungs of surviving animals, while amphotericin B effected sterilization of the lungs in 66% of the survivors.
D000666:Amphotericin B / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D001759:Blastomycosis / Q000188:drug therapy* / Q000382:microbiology; D015725:Fluconazole; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles; D000666:Amphotericin B; D015725:Fluconazole